Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 408 for:    ARIPIPRAZOLE

Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02501109
Recruitment Status : Completed
First Posted : July 17, 2015
Last Update Posted : March 24, 2016
Sponsor:
Information provided by (Responsible Party):
CMG Pharmaceutical Co. Ltd

Brief Summary:
The purpose of this study is to compare the rate and extent of absorption of Aripiprazole Oral Soluble Film 10 mg (Test) versus Abilify® 10 mg tablet (Reference) in healthy male volunteers

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Aripiprazole Phase 1

Detailed Description:
The proposed study is a single centre, bioavailability, open-label, randomized, single-dose, 3-period, 6-sequence, crossover study under fasting conditions. Each volunteer will be given a single dose of the Test formulation in two study periods (with and without water), and a single dose of the Reference formulation (with water) in the other study period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers
Study Start Date : October 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Group A
Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
Drug: Aripiprazole
Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
Other Name: Abilify® 10 mg tablet

Experimental: Group B
Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
Drug: Aripiprazole
Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
Other Name: Abilify® 10 mg tablet

Experimental: Gruop C
Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
Drug: Aripiprazole
Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
Other Name: Abilify® 10 mg tablet




Primary Outcome Measures :
  1. The rate extent of absorption of aripiprazole OSF 10mg versus Abilify ® 10mg tablet [ Time Frame: Baseline to 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female, moderate smoker (no more than 9 cigarettes daily) or non-smoker, ≥45 and ≤65 years of age, with BMI > 18.5 and < 30.0 kg/m2 and body weight 50.0 kg for males and 45.0 kg for females.
  2. Healthy as defined by:
  3. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive method throughout the study and for 42 days after the last study drug administration:
  4. Capable of consent.

Exclusion Criteria:

  1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
  2. Positive urine drug screen at screening.
  3. History of allergic reactions to aripiprazole, dimenhydrinate, benztropine, diphenhydramine or other related drugs.
  4. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first study drug administration.
  5. Positive pregnancy test at screening.
  6. Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
  7. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm), decrease in systolic blood pressure of 20 mmHg or higher, or decrease in diastolic blood pressure of 10 mmHg or higher within 2 to 3 minutes after passing from a supine to a standing position, at screening.
  8. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  9. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year prior to screening.
  10. Use of aripiprazole for a medical condition or in the context of another clinical trial within a period of 42 days prior to the first dosing.
  11. Participation in a clinical trial involving the administration of an investigational or marketed drug within 30 days (90 days for biologics) prior to the first dosing or concomitant participation in an investigational study involving no drug administration.
  12. Use of medication other than topical products without significant systemic absorption and hormonal contraceptives:

    • prescription medication within 14 days prior to the first dosing;
    • over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
    • a depot injection or an implant of any drug (other than hormonal contraceptives) within 3 months prior to the first dosing.
  13. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
  14. Hemoglobin <128 g/L (males) and <115 g/L (females) and hematocrit <0.37 L/L (males) and <0.32 L/L (females) at screening.
  15. Breast-feeding subject.
  16. HAM-D-7 scale score above 3 at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02501109


Sponsors and Collaborators
CMG Pharmaceutical Co. Ltd
Investigators
Layout table for investigator information
Study Director: Byung Jo Kim, M.D. Development Div.

Layout table for additonal information
Responsible Party: CMG Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier: NCT02501109     History of Changes
Other Study ID Numbers: CMG-ARI-140052
First Posted: July 17, 2015    Key Record Dates
Last Update Posted: March 24, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by CMG Pharmaceutical Co. Ltd:
Aripiprazole
Oral Soluble Film
Schizophrenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Aripiprazole
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists